MAVENIR
13.9.2022 09:01:44 CEST | Business Wire | Press release
Deutsche Telekom and Mavenir announced the successful delivery and deployment of cloud-native 5G Core to Deutsche Telekom in Germany. Deutsche Telekom selected Mavenir as the supplier for software applications to run on its defined hardware and the existing Kubernetes-based platform of its German business, ensuring an open architecture approach. As part of the deployment process, the Converged Packet Core was integrated with Telekom’s existing multi-vendor access network and other system components.
The new Converged Packet Core supports data, voice, and messaging services and network slicing. The initial network slicing use case is focused on live video broadcasting. The deployment has been successfully certified against devices from the major terminal vendors.
The Mavenir solution is based on automated software delivery and network upgrades. This will allow new Converged Packet Core services with all the required network functions to be deployed in minutes by using the automation framework of Deutsche Telekom. It is largely self-updating for the entire lifecycle of each application. The platform can automatically synchronize production environment resources and configuration with changes expressed in code. It is therefore less prone to the human errors that come with manual testing and deployment.
Dr. Abdurazak Mudesir, Group CTO Deutsche Telekom, said: “The deployment of a cloud-native Standalone (SA) core marks a key milestone in the evolution of our 5G architecture. This sets us on a path towards a fully automated network with the reliability, massive scale and flexibility required to deliver innovative 5G SA services to our consumer and enterprise customers.”
Pardeep Kohli, Mavenir’s President and CEO, said, “The Mavenir solution deployed with Deutsche Telekom in Germany, creates the foundation for the future introduction of 5G standalone enabling new applications and services to take advantage of 5G features such as low latency and network slicing.”
Key attributes of Mavenir’s solution include:
- Open Architecture: uses Telekom-defined hardware, a Kubernetes-based platform, and the automation framework of Deutsche Telekom.
- Network slicing support: with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design: a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Telekom’s Containers-as-a-Service (CaaS) that can be run on any public, private or hybrid cloud environment.
- Third-party vendor network function (NF) integration: integrated with multiple third-party vendors, including 4G and 5G access network and subscriber management functions.
- Converged architecture: Supports 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform by Deutsche Telekom.
Mavenir’s Converged Packet Core solution is part of its cloud-native MAVcore portfolio built on an open architecture which offers easy scaling of applications and services, hardware decoupling, agility, portability and resilience.
Supporting Material:
- Case Study YouTube Video: GitOps Based Cloud Native 5GC Lifecycle Management – Based on Mavenir 5GC Implementation in Deutsche Telekom Technik with Das Schiff (T-CaaS @ TDG) Platform - Michal Sewera & Samy Nitsche, Deutsche Telekom
- White Paper: Move as Fast as You Can to the 5GC
A TCO Analysis of the Transition to a Converged 5G Core
- Solution Brief: Mavenir’s Converged Packet Core Solution
About Deutsche Telekom: https://www.telekom.com/companyprofile
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release
Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release
NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
